Acute Intravenous Injection of Serelaxin (Recombinant Human Relaxin‐2) Causes Rapid and Sustained Bradykinin‐Mediated Vasorelaxation

BACKGROUND: A recent clinical trial (RELAXin in Acute Heart Failure [RELAX‐AHF]) demonstrated that 48 hours of continuous intravenous infusion of the vasorelaxant peptide serelaxin (recombinant human relaxin‐2) to patients with acute heart failure reduced cardiovascular mortality at 180 days. The pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Leo, Chen Huei, Jelinic, Maria, Parkington, Helena C., Tare, Marianne, Parry, Laura J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959707/
https://www.ncbi.nlm.nih.gov/pubmed/24584737
http://dx.doi.org/10.1161/JAHA.113.000493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959707/
https://www.ncbi.nlm.nih.gov/pubmed/24584737
http://dx.doi.org/10.1161/JAHA.113.000493

Ejemplares similares